CPHI earnings analysis
What we found in CPHI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied filing text does not include current-quarter revenue, EPS, margins, cash flow, balance-sheet amounts, or segment results, so operating trends cannot be assessed from the filing excerpt. The principal disclosed development is that disclosure controls remained ineffective as of June 30, 2026 because of an accounting personnel-related material weakness previously reported in the December 31, 2025 Form 10-K. No quantitative operating guidance was provided.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Financial statements deemed fairly stated
- Management evaluated disclosure controls as of June 30, 2026 and concluded they were not effective. The filing states that the condensed consolidated financial statements were nevertheless fairly stated in all material respects under U.S. GAAP.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material weakness remains unresolved
- Disclosure controls remained ineffective as of June 30, 2026 because of a material weakness related to the lack of accounting and financial-reporting personnel knowledgeable in U.S. GAAP. Management states this weakness was previously disclosed in the Form 10-K for the year ended December 31, 2025.
- Limited market-risk disclosure
- The filing states that the company is a smaller reporting company and is not required to provide the market-risk disclosures under Item 3. As a result, quantitative exposure to market risks is not presented in this report.
What they said about what is next.
No quantitative revenue, EPS, margin, or operating outlook was provided in the supplied filing text.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- In Q1 2026, China Pharma Holdings reported a revenue of $980,000, a decrease from $1.14 million in Q1 2025 due to market competition and changes in procurement policies. Gross margin improved significantly from a loss…
- 10-K · April 1, 2026
- China Pharma positions itself as a China-focused manufacturer of generics and modern TCMs with rights to manufacture 19 products and two GMP-compliant production facilities (20,282.42 sqm and 6,593.20 sqm buildings).…
- 10-Q · August 14, 2025
- China Pharma reported Q2 2025 revenue of $1,025,767 (up from $924,943 a year ago) and a net loss of $528,367 (EPS $(0.16)), with meaningful year‑over‑year margin improvement but continued operating losses and material…
- 10-Q · August 14, 2024
- China Pharma reported Q2 revenue of $924,943, down from $1,097,862 in Q2 2023, with a Q2 net loss of $1,438,130 and EPS of $(0.09). Gross loss widened to $(1,015,386) and operating loss to $(1,391,521), while cash…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CPHI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever